Thiotepa is a chemotherapy drug used to treat certain cancers including breast cancer, ovarian cancer, and bladder cancer. It works by damaging cancer cell DNA to stop them from growing and dividing.[2] Tepadina is currently approved and in use across 42 indications[4].[1]
Tepadina is one of 573 small molecule programs targeting Unspecified Peripheral T-Cell Lymphoma. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
370 competitors in Lymphoma
Tepadina
Zofran
Cabenuva
Nuvigil
Emend
Kenalog
Systemic Therapy
Elitek
Decadron
Solu-Medrol
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
THIOTEPA
NDA NDA011683
Dec 22, 1994
THIOPLEX
NDA NDA020058
Jan 26, 2017
TEPADINA
NDA NDA208264
Dec 27, 2019
TEPADINA AND SODIUM CHLORIDE, TEPADINA
NDA NDA208264
Mar 13, 2020
TEPADINA AND SODIUM CHLORIDE, TEPADINA
NDA NDA208264
Jun 25, 2024
TEPYLUTE
NDA NDA216984
Apr 10, 2025
TEPADINA AND SODIUM CHLORIDE, TEPADINA
NDA NDA208264
Oct 2, 2025
TEPADINA AND SODIUM CHLORIDE, TEPADINA
NDA NDA208264
Jan 15, 2026
TEPADINA AND SODIUM CHLORIDE, TEPADINA
NDA NDA208264
Sources